- Home
- IMCR vs KALU Comparison
IMCR vs KALU Comparison
Compare IMCR & KALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- KALU
- Stock Information
- Founded
- IMCR 2008
- KALU 1946
- Country
- IMCR United Kingdom
- KALU United States
- Employees
- IMCR N/A
- KALU N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- KALU Metal Fabrications
- Sector
- IMCR Health Care
- KALU Industrials
- Exchange
- IMCR Nasdaq
- KALU Nasdaq
- Market Cap
- IMCR 1.5B
- KALU 1.2B
- IPO Year
- IMCR 2021
- KALU 1991
- Fundamental
- Price
- IMCR $32.77
- KALU $82.22
- Analyst Decision
- IMCR Buy
- KALU Buy
- Analyst Count
- IMCR 10
- KALU 3
- Target Price
- IMCR $58.13
- KALU $69.00
- AVG Volume (30 Days)
- IMCR 445.1K
- KALU 129.3K
- Earning Date
- IMCR 08-07-2025
- KALU 07-23-2025
- Dividend Yield
- IMCR N/A
- KALU 3.75%
- EPS Growth
- IMCR N/A
- KALU 0.39
- EPS
- IMCR N/A
- KALU 3.06
- Revenue
- IMCR $333,581,000.00
- KALU $3,063,900,000.00
- Revenue This Year
- IMCR $26.82
- KALU $11.04
- Revenue Next Year
- IMCR $8.15
- KALU $7.33
- P/E Ratio
- IMCR N/A
- KALU $26.78
- Revenue Growth
- IMCR 25.75
- KALU 1.56
- 52 Week Low
- IMCR $23.15
- KALU $46.81
- 52 Week High
- IMCR $41.54
- KALU $100.07
- Technical
- Relative Strength Index (RSI)
- IMCR 45.73
- KALU 67.30
- Support Level
- IMCR $30.76
- KALU $75.76
- Resistance Level
- IMCR $32.55
- KALU $81.90
- Average True Range (ATR)
- IMCR 1.39
- KALU 2.23
- MACD
- IMCR -0.41
- KALU 0.05
- Stochastic Oscillator
- IMCR 19.09
- KALU 85.80
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.